MARKET

SLP

SLP

Simulations Plus Inc
NASDAQ
43.96
-0.28
-0.63%
Opening 09:41 07/17 EDT
OPEN
43.64
PREV CLOSE
44.24
HIGH
44.11
LOW
43.64
VOLUME
2.39K
TURNOVER
0
52 WEEK HIGH
52.69
52 WEEK LOW
32.60
MARKET CAP
879.54M
P/E (TTM)
92.74
1D
5D
1M
3M
1Y
5Y
1D
Simulations Plus Initiated at Market Perform by JMP Securities
Dow Jones · 1d ago
JMP Securities Initiates Coverage On Simulations Plus with Market Perform Rating
Benzinga · 1d ago
Simulations Plus: A Strong Hold Amidst Growth and Strategic Acquisitions
TipRanks · 1d ago
Weekly Report: what happened at SLP last week (0708-0712)?
Weekly Report · 2d ago
Simulations Plus (SLP) Ties Up With ICCS for Chemical Safety
NASDAQ · 5d ago
Simulations Plus Announces New Research Project With The International Collaboration On Cosmetics Safety To Evaluate The Use Of Physiologically-Based Kinetic Modeling Approaches To Advance Animal-Free Science For Cosmetics And Other Non-Pharmaceutical Ingredients
Simulations Plus, Inc. Will evaluate the use of physiologically-based kinetic modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients. The company is a leading provider of simulation to the biopharma industry. Objective to define best practices to support animal- free safety assessment of new chemicals.
Benzinga · 6d ago
Simulations Plus: Steady Growth, But What About The Margins?
Simulations Plus, Inc. Has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. The company is a leading provider of software and consulting services in the drug development market. A $5 stock in 2014, the company is now valued at around 12 times sales.
Seeking Alpha · 6d ago
Weekly Report: what happened at SLP last week (0701-0705)?
Weekly Report · 07/08 09:20
More
About SLP
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.

Webull offers Simulations Plus Inc stock information, including NASDAQ: SLP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLP stock methods without spending real money on the virtual paper trading platform.